10x Genomics’ earnings call highlighted a business leaning on consumables strength and innovation to offset a harsh capital spending backdrop. For investors, the story is one of prudent financial ...

The biotechnology services provider expanded its offerings with advanced gene expression analysis technology for research ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript February 12, 2026 10x Genomics, Inc. beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.19. Operator: Thank you ...

Since the launch of the Hong Kong laboratory in July 2025, Omics Empower has supported research teams with local single-cell sequencing and spatial transcriptomics services. Faster processing helps ...

Genomics (NASDAQ:TXG) reported fourth-quarter revenue of $166 million, surpassing the high end of its guidance range, as ...

Genomics is collaborating with PharosAI and leading UK institutions to build a large multimodal cancer dataset using its ...

On 4, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer samples into high-resolution, multimodal datasets, backed by £18.9 million in UK government ...

Scientist John Cleary points to a screen on the Xenium Analyzer in the Next Generation Transcriptomic Facility at the University at Albany on Tuesday in Albany. Around 50 to 70 diseases are believed ...

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region ASTRA will bring together molecular and spatial data ...

We combine advanced technologies such as spatial transcriptomics, multiplexed imaging, and in situ sequencing to map cellular components in their native tissue context. Obtain high-resolution data ...

PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ:TXG), a life sciences technology company with a market capitalization of $1.7 billion and impressive gross margins of nearly 70%, announced Tuesday the ...